M

Moderna

Develops mRNA-based medicines for health

Head of Translational Medicine

Full-TimeUpdated on 10/23/2026
$272.2k - $490.1k+ Annual discretionary bonus + Other incentive compensation + Equity award
Expert
Bachelor's, PharmD, PhD, MD
Cambridge, MA, USA
In PersonIn-person work model: 70% in-office.
Biology & BiotechTranslational Research & Bench Biology, Clinical Research Operations

About the job

Requirements
  • An advanced degree (PhD, MD, PharmD, or equivalent) in a relevant scientific discipline.
  • At least 15 years of experience across translational science, clinical pharmacology, and/or drug development, including at least 10 years in a leadership role.
  • Deep expertise spanning translational medicine, biomarker strategy, experimental medicine, and quantitative pharmacology.
  • Ability to develop scientific hypotheses on human disease and translate them between the clinic and the laboratory.
  • Demonstrated success influencing development strategy, including dose selection, study design, and regulatory interactions.
  • Strong understanding of the end-to-end drug development process, from discovery through commercialization.
  • Strong publication record and ability to represent the company externally to the scientific community.
  • Proven ability to lead large multidisciplinary teams and operate effectively in a complex matrix environment.
  • Experience mentoring, hiring, and growing talented scientists.
  • Track record of driving innovation and delivering measurable impact across a portfolio.
  • Ability to translate complex science into strategic decisions.
  • Employment is contingent on the ability to access export-controlled information in accordance with U.S. law; candidates who are not U.S. citizens, lawful permanent residents, asylees, or refugees may be considered contingent on obtaining a required export-control license.
Responsibilities
  • Define and lead an integrated, end-to-end translational strategy across Translational Medicine, Translational Research, and Clinical Pharmacology/Pharmacometrics, spanning discovery through lifecycle management.
  • Establish a unified framework connecting biological insights, biomarkers, and quantitative pharmacology to enable rapid, data-driven decision-making.
  • Align translational strategies with program and portfolio objectives, including development pathways, target product profiles, and regulatory strategies.
  • Lead translational input into governance and ensure rigorous, data-driven go/no-go decisions across the pipeline.
  • Lead and unify a high-performing, multidisciplinary translational organization, connecting scientific, clinical, and quantitative capabilities into a cohesive, integrated model.
  • Serve as a senior leader and thought partner across Research and Development, influencing strategy, prioritization, and execution.
  • Represent the company's translational strategy externally, engaging regulators, scientific leaders, and partners to shape scientific direction and advance approaches across the portfolio.
  • Lead execution of early clinical translational plans, including biomarker implementation, endpoint operationalization, and data interpretation to enable proof-of-concept decisions.
  • Partner with clinical development to translate scientific hypotheses into actionable clinical strategies and high-quality study execution.
  • Define and validate novel endpoints and patient stratification approaches to enable early decision-making and differentiation.
  • Serve as a senior clinical leader in internal and external settings, including study teams, governance, and interactions with investigators and key opinion leaders.
  • Build and advance translational capabilities, including molecular assays, sequencing, immune monitoring, and companion diagnostics, to enable patient selection and mechanistic insight.
  • Oversee generation and delivery of stage-appropriate translational data packages to support IND readiness and early clinical development.
  • Drive forward and reverse translation so clinical insights inform discovery, platform innovation, and next-generation therapeutics.
  • Lead development of patient identification, pharmacodynamic, and disease monitoring strategies to support clinical entry and advancement.
  • Drive quantitative integration of PK/PD, exposure-response, and modeling and simulation into program-level decision-making and trial design.
  • Lead pharmacology contributions to regulatory strategy, including authorship and defense of clinical pharmacology components in health authority interactions.
  • Ensure innovative application of pharmacometrics to dose prediction, first-in-human studies, and lifecycle optimization across the pipeline.
  • Represent clinical pharmacology in governance and partner cross-functionally to inform critical dose and development decisions across programs.
Desired Qualifications
  • Experience with companion diagnostics.
  • Leadership roles contributing to BLAs for oncology or immunology programs.
  • Deep expertise in immunology, oncology, and autoimmune disease.
  • A network of external academic experts.

About the company

Moderna develops medicines built on messenger RNA (mRNA). Its products use mRNA delivered into cells to instruct them to produce specific proteins that can prevent or treat disease, with vaccines being a primary example. In practice, a dose delivers engineered mRNA into the body, cells translate it into a target protein, and the immune system responds or the protein modulates biology to combat disease. Moderna differentiates itself through its focus on building a whole mRNA medicines platform and in-house capabilities for designing, manufacturing, and scaling mRNA therapies, including rapid development and large-scale production. Its goal is to create a new category of medicines based on mRNA that can improve how diseases are discovered, developed, and treated, ultimately improving patient outcomes.

Company Size

5,001-10,000

Company Stage

IPO

Headquarters

Cambridge, Massachusetts

Founded

2010

Get referred to Moderna

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • September 2026 convertible notes raised $3 billion for oncology growth and debt flexibility.
  • April 21, 2026 European Commission approval made mCombriax the first authorized flu-COVID combo vaccine.
  • Second-quarter 2026 guidance targets up to 10% revenue growth and year-end cash of $4.7 billion.

What critics are saying

  • September 28, 2026, Delaware kept Bayer's mRNA patent case alive against Moderna.
  • July 15, 2026, Sanofi sued Moderna over COVID vaccine patents in New Jersey.
  • If intismeran fails beyond melanoma, Moderna remains a shrinking vaccine company.

What makes Moderna unique

  • Moderna's mRNA platform spans vaccines, oncology, and rare disease, unlike one-product peers.
  • September 30, 2026, Moderna added a COO to scale intismeran autogene manufacturing.
  • Bancel says Moderna owns mutation-selection software for personalized vaccines and synthetic, cell-free production.

Help us improve and share your feedback! Did you find this helpful?

Benefits

  • Health Insurance
  • Dental Insurance
  • Vision Insurance
  • Life Insurance
  • Disability Insurance
  • Health Savings Account/Flexible Spending Account
  • Unlimited Paid Time Off
  • Paid Vacation
  • Paid Sick Leave
  • Paid Holidays
  • Sabbatical Leave
  • Hybrid Work Options

Growth & Insights and Company News

6 month growth

0%

1 year growth

0%

2 year growth

0%
Yahoo Finance
Oct 22nd, 2026
Moderna sinks 18% after leak of melanoma vaccine data showing 42% lower recurrence risk

Moderna shares fell 18% after detailed Phase 3 results for its personalised melanoma vaccine, developed with Merck, appeared online two days before their scheduled presentation. The data surfaced on medical news site Oncology Central and was taken down shortly afterwards. Trading in Moderna was halted for volatility. The leaked data still looks positive. Adding the vaccine, intismeran autogene, to Merck's Keytruda cut the risk of recurrence or death by 42% versus Keytruda alone. After two years, 82.2% of patients on the combination were alive and cancer-free, against 70% on Keytruda alone. The trial enrolled 1,137 patients. The stock had risen more than eightfold this year, and traded at about 52x forward sales before the drop. The 42% figure also trails the 49% from the smaller Phase 2b trial. Full results are due at the ESMO Congress on Saturday.

Yahoo Finance
Oct 21st, 2026
Moderna soars 600% to $90B market cap, but valuation leaves no margin for error

Moderna (NASDAQ: MRNA) has soared over 600% this year, making it the best performer among large-cap healthcare stocks. Eli Lilly gained 16% and Johnson & Johnson 22%. The rally followed US approval of mFLUSIVA, an influenza vaccine for people aged 50 and older. Moderna also said its personalised cancer vaccine, intismeran autogene, significantly improved recurrence-free survival in certain melanoma patients when combined with Merck's Keytruda. It is the first personalised vaccine to produce positive Phase 3 results. Moderna's market cap now stands at $90 billion. The average analyst price target of $123.61 implies a downside of about 45%. In the first six months of 2026, revenue rose 113.6% to $534 million, but net loss widened to $2.1 billion from $1.8 billion.

Yahoo Finance
Oct 21st, 2026
ServiceNow and Kinder Morgan are large-cap picks to watch; Moderna's $96.65B value underwhelms

StockStory, a stock research service, named two large-cap stocks to watch and one to avoid. It advises steering clear of Moderna, which has a market cap of $96.65 billion. Sales fell 20.5% annually over five years, and earnings per share dropped 24.5% annually. Its free cash flow margin fell 95.9 percentage points. The stock trades at $241.71, or 44.1x forward price-to-sales. ServiceNow ($154.6 billion market cap) grew annual recurring revenue 22.3% over the last year and has a free cash flow margin of 33.4%. It trades at $148.56 per share. Kinder Morgan ($74.75 billion market cap) reported $17.96 billion in revenue. Its shares trade at $33.64, or 22.5x forward earnings.

Yahoo Finance
Oct 19th, 2026
Moderna, Chemed and 10x Genomics: three healthcare stocks to avoid despite a 25.2% sector rally

Healthcare stocks have gained 25.2% over the past six months, beating the S&P 500 by 16.3 percentage points. Even so, StockStory warns that heavy regulation can hurt earnings, and names three stocks to avoid. Moderna, valued at $87.04 billion, has seen sales fall 20.5% a year over five years. Earnings per share dropped 24.5% annually, and the stock trades at 46x forward price-to-sales. Chemed, worth $6.67 billion, grew revenue 4.1% a year over five years, slower than its peers. Its adjusted operating margin fell 3.9 percentage points, and it trades at 20x forward earnings. 10x Genomics, valued at $9.10 billion, saw revenue decline 1.2% annually over two years to $616.9 million. Its returns on capital are negative.

CNBC
Oct 14th, 2026
Merck CEO expects Moderna cancer vaccine's six-week production time to shorten

Merck chief executive officer Rob Davis expects the company's personalised cancer vaccine with Moderna to become faster to make over time. He told CNBC the current timeline is six weeks, from sequencing a patient's tumour to delivering the shot to the hospital. "I do think over time you're going to see that timeline shortened," Davis said. For now, the focus is on readying supply and the market. The vaccine targets the mutations in each patient's tumour and is paired with Merck's immunotherapy Keytruda. In August, the companies released positive initial late-stage data in melanoma patients. Trials are also under way in lung, bladder, and kidney cancers. Davis spoke as Merck opened its 120,000-square-foot research facility, Advance, in West Point, Pennsylvania.